Advised on sale of biopharmaceutical company focused on cancer treatments
Subscribe to Transaction NewsAdvised on sale of biopharmaceutical company focused on cancer treatments
Subscribe to Transaction NewsJohn and his team served as exclusive financial advisor to the board of IGDRASOL, Inc. Our services were in connection with the company’s sale to Sorrento Therapeutics, a publicly traded, development-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel and proprietary biotherapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic, and infectious diseases. IGDRASOL’s lead compound, Cynviloq, is a next-generation paclitaxel formulation (chemotherapy agent) in development for the treatment of solid tumors, including metastatic breast cancer, non-small-cell lung cancer, and pancreatic cancer. Cynviloq is currently approved and marketed in several countries, including South Korea for metastatic breast cancer and non-small-cell lung cancer under the trade name Genexol-PM.
Note: This work was performed prior to joining Stout.